Hemolysis contributes to the pathophysiology of sickle cell disease by reducing nitric oxide bioavailability.
 Modified from Ataga KI, Stocker J. Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia. Expert Opin Investig. Drugs 2009;18:231–239.
 ADMA indicates asymmetric dimethylarginine; Hb, hemoglobin; HbS, sickle hemoglobin; RBC, red blood cell.